The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

BACKGROUND: The 21-gene Recurrence Score (RS) result predicts outcome and chemotherapy benefit in node-negative and node-positive (N+), estrogen receptor-positive (ER+) patients treated with endocrine therapy. The purpose of this study was to evaluate the prognostic impact of RS results in N+, hormo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Penault-Llorca, Frédérique, Filleron, Thomas, Asselain, Bernard, Baehner, Frederick L., Fumoleau, Pierre, Lacroix-Triki, Magali, Anderson, Joseph M., Yoshizawa, Carl, Cherbavaz, Diana B., Shak, Steven, Roca, Lise, Sagan, Christine, Lemonnier, Jérôme, Martin, Anne-Laure, Roché, Henri
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5936023/
https://ncbi.nlm.nih.gov/pubmed/29728098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4331-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados